TG Therapeutics, Inc. $TGTX Stock Holdings Lessened by Penn Capital Management Company LLC

Posted by Geri Gentry on Nov 10th, 2026

Penn Capital Management Company LLC cut its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 10.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 480,881 shares of the biopharmaceutical company’s stock after selling 55,186 shares during the period. TG Therapeutics makes up about 2.0% of Penn Capital Management Company LLC’s holdings, making the stock its 3rd biggest position. Penn Capital Management Company LLC owned 0.31% of TG Therapeutics worth $26,876,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TGTX. Allspring Global Investments Holdings LLC boosted its position in shares of TG Therapeutics by 36.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 310,856 shares of the biopharmaceutical company’s stock valued at $16,668,000 after purchasing an additional 83,426 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in TG Therapeutics during the 3rd quarter worth about $497,000. Calamos Advisors LLC acquired a new stake in TG Therapeutics during the 3rd quarter worth about $1,280,000. Kestra Advisory Services LLC lifted its stake in TG Therapeutics by 15.9% during the third quarter. Kestra Advisory Services LLC now owns 4,610 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 631 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its stake in TG Therapeutics by 6.3% during the third quarter. Oregon Public Employees Retirement Fund now owns 31,862 shares of the biopharmaceutical company’s stock valued at $1,777,000 after buying an additional 1,900 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on TGTX. Zacks Research upgraded shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. HC Wainwright restated a “buy” rating and set a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, September 1st. Weiss Ratings upgraded shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, B. Riley Financial raised their price objective on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $63.00.

View Our Latest Stock Report on TG Therapeutics

TG Therapeutics Trading Up 5.9%

Shares of NASDAQ TGTX opened at $63.38 on Tuesday. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $63.60. The firm has a market capitalization of $9.70 billion, a PE ratio of 23.13, a PEG ratio of 2.60 and a beta of 1.89. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The business has a 50-day moving average price of $55.99 and a two-hundred day moving average price of $44.66.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last released its earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.02). The business had revenue of $259.94 million for the quarter, compared to analysts’ expectations of $245.47 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The company’s revenue was up 60.8% compared to the same quarter last year. During the same period last year, the firm earned $2.43 EPS. As a group, analysts predict that TG Therapeutics, Inc. will post 0.92 earnings per share for the current fiscal year.

More TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

Positive Sentiment: Third-quarter revenue was $259.9 million, up 60.8% year over year and above estimates of about $245.5 million. TG Therapeutics Reports Third Quarter 2026 Financial Results
Positive Sentiment: The company raised its 2026 revenue outlook to $1.0 billion, ahead of the roughly $961 million consensus. CEO Michael Weiss also said global revenue could exceed $1 billion, with BRIUMVI driving growth. TG Therapeutics CEO sees global revenue exceeding $1B in 2026
Neutral Sentiment: EPS was $0.35. That topped Zacks’ $0.28 estimate, but was below other reported consensus figures around $0.37; earnings were also lower than the $2.43 reported a year earlier. TG Therapeutics beats Q3 earnings and revenue estimates

Insider Activity

In related news, Director Laurence Charney sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the sale, the director directly owned 168,640 shares in the company, valued at approximately $9,268,454.40. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.87% of the stock is owned by company insiders.

TG Therapeutics Profile

(Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe.